News
NICE recommendation expands patient eligibility for AbbVie’s Ozurdex
Treatment becomes an option for treating visual impairment caused by diabetic macular oedema, regardless of lens status.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Treatment becomes an option for treating visual impairment caused by diabetic macular oedema, regardless of lens status.